Ascletis Pharma Inc Stock price
Compare with Peer Group
Is Ascletis Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Ascletis Pharma Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Ascletis Pharma Inc forecast:
Analyst Opinions
9 Analysts have issued a Ascletis Pharma Inc forecast:
Don't miss a Thing! We will send you all news about Ascletis Pharma Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The firm focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The firm's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The firm conducts its business in the domestic and overseas markets.
| Head office | Cayman Islands |
| CEO | Dr. Wu |
| Employees | 202 |
| Website | www.ascletis.com |


